Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive aripiprazole for obsessive-compulsive symptoms in bipolar disorder
IRCT20230814059145N1Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of aripiprazole in bipolar disorder (BD) (2 arms), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoints: Severity of obsession, Severity of depression and 1 more. Started Nov 2023; status: completed.
02
Drugs
aripiprazole
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on IRCT20230814059145N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230814059145N1.